Integrated Filing — IndAS



General information about company

Scrip Code 524372
NSE Symbol ORCHPHARMA
MSEI Symbol NOTLISTED
ISIN INE191A01027
Name of company ORCHID PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 14-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 11-08-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 14-08-2026   14:00:00
End date and time of board meeting 14-08-2026   18:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 18-01-2025
Indicate Company website link for updated RPT policy of the Company https://www.orchidpharma.com/investors
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable as the Company has not defaulted on Loans and Debt Securities during the reporting period.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 36,832.71 1,23,277.84
Other income 1,372.81 5,648.69
Total income 38,205.52 1,28,926.53
2 Expenses
(a) Cost of materials consumed 20,983.93 77,139.16
(b) Purchases of stock-in-trade 47.59 168.72
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 3,512.34 7,138.39
(d) Employee benefit expense 2,633.08 11,432.05
(e) Finance costs 194.97 896.15
(f) Depreciation, depletion and amortisation expense 1,118.44 4,335.60
(f) Other Expenses
1 Other Expenses 6,426.86 23,621.17
Total other expenses 6,426.86 23,621.17
Total expenses 34,917.21 1,24,731.24
3 Total profit before exceptional items and tax 3,288.31 4,195.29
4 Exceptional items (22.02) (733.29)
5 Total profit before tax 3,266.29 3,462.00
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax 0.00 0.00
9 Total tax expenses 0.00 0.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 3,266.29 3,462.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 3,266.29 3,462.00
17 Other comprehensive income net of taxes 130.27 131.76
18 Total Comprehensive Income for the period 3,396.56 3,593.76
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 5,988.52 5,988.52
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 1,58,679.07
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 5.45 5.78
Diluted earnings (loss) per share from continuing operations 5.45 5.78
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 5.45 5.78
Diluted earnings (loss) per share from continuing and discontinued operations 5.45 5.78
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above Revised results for the quarter and year ended March 31, 2026 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on August 14, 2026.The statutory auditors of the company have expressed an unmodified opinion on the audited Standalone results and a modified opinion on the audit of the Consolidated results. 2. The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards (“Ind AS”) as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. 3. a) The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the ‘New Labour Codes’, which became effective from 21st November 2025. However, the new Rules are yet to be notified even as on date. During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company recognised a provision of Rs. 711.27 lakhs towards incremental estimated liabilities for past service cost relating to gratuity and leave, which was disclosed under “Exceptional items”. Thereafter, based on subsequent FAQ’s and clarifications issued by the Ministry of Labour, deliberations at various forums and detailed examination of various provisions of the above new Labour Codes, the Company, based on Actuarial Valuation, has determined that the incremental estimated liabilities as on March 31, 2026 on account of past service cost in relation to Gratuity and Leave liability amounted to only Rs.733.29 Lakhs. Hence the additional provision of Rs.22.02 Lakhs has been provided in the March 2026 quarter under “Exceptional items”. The net impact of such re assessment has been appropriately accounted for in the statement of profit and loss. The Company continues to monitor the finalisation of Central / State Rules and further clarifications from the Government on other aspects of the Labour Codes and will account for any additional impact, if required, based on such developments. 4. 99,02,705 fully paid up Equity Shares of face value Rs. 10/- each of the Company was allotted on 27th June 2023 by way of Qualified Institutional Placement (QIP) whereby proceeds of Rs.39180 Lakhs (Net of Share issue expenses) was raised. As on March 31, 2026 the entire net Proceeds of Rs.39180 Lakhs was received by the Company under the QIP and the Statement of Net funds raised and its utilisation is furnished below : Statement of QIP Net Funds raised and utilisation Particulars Amount as stated in Total amount utilised * Balance amount as on Remarks the Offer Document upto March 31, 2026 on March 31, 2026 kept Rs. In Lakhs(revised) Rs. In Lakhs in Fixed Deposits in lakhs 1)Investment in OBPL, subsidiary, for setting up Jammu Manufacturing Facility 13500 7302 6198 2)Repayment/prepayment, in full or in part, of certain outstanding borrowings availed by the company 19546 19546 - 3)Funding capital expenditure requirements for setting up a new block at the API facility of the Company in Alathur, Tamil Nadu 36 36 - 4)General corporate purposes 6372 6372 0 # Total 39454 33256 6198 # As per QIP Offer Document the amount allocated for General Corporate Purpose (GCP) was Rs. 6098 Lakhs which was based on the propsoed net proceeds after issue expenses being Rs.39180 Lakhs. However, net proceeds transferred to Monitoring Agency Account was Rs. 39454 Lakhs as against the proposed Net Proceeds of Rs. 39180 Lakhs, therefore surplus Amount of Rs. 274 Lakhs has been included in GCP Balance as on June 30, 2026. The allocation among the objects has been revised vide Shareholder's Resolution dated September 20, 2025. *Balance amount excludes the interest earned on the Unutilized QIP funds kept in fixed deposits. 5. The operations of the Company falls under a single operating segment i.e., Pharmaceuticals in accordance with Ind AS 108 Operating Segments and hence no reporting as per Ind AS 108 is applicable. 6. The figures for the quarters ended 31st March, 2026 and 31st March 2026 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the relevant financial years which were subjected to limited review. 7. In accordance to the provisions of Section 230-232 of the Companies Act, 2013 read with the applicable Rules made thereunder, the Board of Directors of Orchid Pharma Limited (“the Company” or “Transferee Company”) had approved the Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited (“Dhanuka” or “Transferor Company”) and Orchid Pharma Limited and their respective shareholders and creditors (“the Scheme”), pursuant to which Dhanuka was proposed to be amalgamated with and into the Company, with April 01, 2024 as the Appointed Date. The Scheme was subsequently considered and sanctioned by the Hon’ble National Company Law Tribunal, Chennai Bench (“NCLT”) vide its order dated June 05, 2026. The Company obtained the certified copy of the said order and, upon filing of the same with the Registrar of Companies, Chennai, on July 10, 2026, the Scheme became effective (“Effective Date”). Pending receipt of the order of the Hon’ble NCLT and effectiveness of the Scheme, the financial results of the Company for the quarter and year ended March 31, 2026 were approved by the Board of Directors at its meeting held on May 25,2026, without giving effect to the Scheme. Subsequent to the approval of the financial results by the Board, the Scheme was sanctioned by the Hon’ble NCLT vide Order dated June 05, 2026 and which became effective on July 10, 2026. Accordingly, in accordance with the requirements of Appendix C to Ind AS 103 – Business Combinations, read with the applicable provisions of the Scheme, the amalgamation has been given effect to from the Appointed Date and the standalone and consolidated financial results for the quarter and year ended March 31, 2026 have been revised/restated solely to give effect to the amalgamation. The corresponding comparative information has also been revised, wherever applicable, to give effect to the amalgamation from the Appointed Date. The revision includes the consequential impact of the amalgamation on the assets, liabilities, equity, reserves and other relevant financial statement items of the Company. The revision of the standalone and consolidated financial results has been carried out solely for giving effect to the aforesaid amalgamation pursuant to the Scheme, and no other adjustments have been made to the financial results originally approved by the Board of Directors on May 25, 2026, except for those consequentially arising from the accounting of the amalgamation. 8 The Company has successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH, Germany and Allecra Therapeutics SAS, France on October 29,2025 and August 01,2025 respectively. After the successful completion of above transactions, Orchid Pharma Limited now possesses 100% global ownership of Enmetazobactam (International Brand Name known as EXBLIFEP) (known as Orblicef in India), consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India, back to India. 9 The Company have acquired 100% Share Capital of Weilchensee 1272. V V GmbH, a Company incorporated under laws of Germany, now a Wholly owned subsidiary renamed as Orchid Pharma Europe GmbH w.e.f. July 30, 2025. 10 Figures of the previous period have been regrouped/reclassified/restated wherever considered necessary.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 66,507.07
Capital work-in-progress 9,499.77
Investment property 0.00
Goodwill 0.00
Other intangible assets 59.59
Intangible assets under development 7,307.98
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 8,759.22
Trade receivables, non-current 0.00
Loans, non-current 18,249.10
Other non-current financial assets
1 Right to use Assets 492.89
2 Other financials assets 661.12
Total of other non-current financial assets 1,154.01
Total non-current financial assets 28,162.33
Deferred tax assets (net) 5,981.96
Other non-current assets
1 Other non current assets 4,100.73
Total of other non-current assets 4,100.73
Total non-current assets 1,21,619.43
2 Current assets
Inventories 37,231.10
Current financial asset
Current investments 0.00
Trade receivables, current 38,135.01
Cash and cash equivalents 130.46
Bank balance other than cash and cash equivalents 6,520.83
Loans, current 0.00
Other current financial assets
Total of other current financial assets 106.27
Total current financial assets 44,892.57
Current tax assets (net) 0.00
Other current assets
1 Other current assets 6,020.17
Total of other current assets 6,020.17
Total current assets 88,143.84
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 2,09,763.27
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 5,988.52
Other equity 1,58,679.07
Total equity attributable to owners of parent 1,64,667.59
Non controlling interest
Total equity 1,64,667.59
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 3,562.98
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 lease liabilities 472.48
Total of other non-current financial liabilities 472.48
Total non-current financial liabilities 4,035.46
Provisions, non-current 1,344.93
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
1 non-current liabilities 211.55
Total of other non-current liabilities 211.55
Total non-current liabilities 5,591.94
Current liabilities
Current financial liabilities
Borrowings, current 8,790.88
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,029.75
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 26,608.30
Total Trade payable 27,638.05
Other current financial liabilities
1 lease liabilities 38.54
2 Other current financial liabilities 134.32
Total of other current financial liabilities 172.86
Total current financial liabilities 36,601.79
Other current liabilities 2,821.51
1 Other current liabilities 2,821.51
Total of other current liabilities 2,821.51
Provisions, current 80.44
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 39,503.74
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 45,095.68
Total equity and liabilites 2,09,763.27
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 items that will not be recclassified as profit or loss 130.27 131.76
Total Amount of items that will not be reclassified to profit and loss 130.27 131.76
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 130.27 131.76



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,462.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 896.15
Adjustments for decrease (increase) in inventories 8,505.43
Adjustments for decrease (increase) in trade receivables, current (3,960.52)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 632.23
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 45.36
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 1,053.38
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 4,335.60
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (51.98)
Adjustments for provisions, non-current 1,646.56
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (739.71)
Adjustments for dividend income 0.00
Adjustments for interest income 2,442.48
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 620.46
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 10,540.48
Net cash flows from (used in) operations 14,002.48
Dividends received 0.00
Interest paid (239.55)
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 14,242.03
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 2,116.98
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 911.01
Purchase of property, plant and equipment 17,182.46
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 7,424.78
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.08
Interest received 2,768.29
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 11,413.09
Net cash flows from (used in) investing activities (11,631.75)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 2,561.98
Repayments of borrowings 5,628.75
Payments of lease liabilities 0.00
Dividends paid 0.00
Interest paid 1,007.22
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (4,073.99)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (1,463.71)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (1,463.71)
Cash and cash equivalents cash flow statement at beginning of period 1,594.17
Cash and cash equivalents cash flow statement at end of period 130.46





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Singhi & Co. Yes 31-08-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Orchid Pharma Limited Dhanuka Laboratories Limited Holding Company Purchase of goods or services 5,000.00 Approved 664.04 0.00 549.83
2 Orchid Pharma Limited Dhanuka Laboratories Limited Holding Company Any other transaction lease rents recived 250.00 Approved 147.54 0.00 55.83
3 Orchid Pharma Limited Dhanuka Laboratories Limited Holding Company Sale of goods or services 5,000.00 Approved 1,869.82 113.45 1,983.28
4 Orchid Pharma Limited DHANUKA AGRITECH LIMITED Related Party under sec2(76)(1v) Any other transaction lease rents paid 150.00 Approved 42.78 0.00 0.57
5 Orchid Pharma Limited DHANUKA AGRITECH LIMITED Related Party under sec2(76)(1v) Any other transaction rent deposit paid Approval included with lease rents 0.00 19.10 0.00
6 Orchid Pharma Limited ORBION PHARMACEUTICALS PRIVATE LIMITED Associate Company Sale of goods or services 500.00 Approved 15.67 0.00 0.00
7 Orchid Pharma Limited ORCHID BIO-PHARMA LIMITED Wholly Owned Subsidiary company Loan 35,000.00 Approved 4,035.91 13,130.33 17,858.81 Loan 0.1200 As per loan agreement Unsecured For investing in capital project
8 Orchid Pharma Limited ORCHID BIO-PHARMA LIMITED Wholly Owned Subsidiary company Interest received Appoval included with loan given 692.57 0.00 0.00
9 Orchid Pharma Limited ORCHID BIO-PHARMA LIMITED Wholly Owned Subsidiary company Any other transaction corporate gaurantee commission received 600.00 Approved 330.31 0.00 195.51
10 Orchid Pharma Limited OTSUKA CHEMICAL (INDIA) PVT LTD Related Party under sec2(76)(1v) Purchase of goods or services 40,000.00 Approved 5,851.04 983.07 3,302.11
11 Orchid Pharma Limited Synmedic Laboratories Related Party under sec2(76)(iii) Purchase of goods or services 100.00 Approved 3.24 0.01 0.01
12 Orchid Pharma Limited Synmedic Laboratories Related Party under sec2(76)(iii) Sale of goods or services 500.00 Approved 30.83 7.02 10.12
13 Orchid Pharma Limited Synmedic Laboratories Related Party under sec2(76)(iii) Any other transaction lease rents recived 200.00 Approved 100.45 0.00 38.01
14 Orchid Pharma Limited Orchid Pharma Europe GMBH Wholly Owned Subsidiary company Any other transaction Share capital invested N.A 0.00 28.95 28.95
15 Orchid Pharma Limited Orchid Pharma Europe GMBH Wholly owned Subsidiary company Loan N.A 384.09 0.00 384.09 Loan 0.0600 As per loan agreement Unsecured For meeting business requirement
16 Orchid Pharma Limited Orchid Pharma Europe GMBH Wholly owned Subsidiary company Interest received N.A 6.19 0.00 6.19
17 Orchid Pharma Limited ORCHID BIO-PHARMA LIMITED Wholly owned Subsidiary company Any other transaction Corporate guarantee given N.A 2,582.00 0.00 0.00
Total value of transaction during the reporting period 16,756.48